Prevalence and Determinants of Transient Congenital Hypothyroidism in Children With Eutopic Gland in France: A Retrospective Cohort Study.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
24 03 2022
Historique:
received: 02 08 2021
pubmed: 2 12 2021
medline: 16 4 2022
entrez: 1 12 2021
Statut: ppublish

Résumé

The increase in the incidence of congenital hypothyroidism (CH) reported worldwide may partly be explained by an increase in the transient form of CH. We aimed to estimate the proportion of transient CH (TCH) in France, and to identify associated neonatal and young child characteristics. We used probabilistic record linkage to link children with eutopic gland born between 2006 and 2012 recorded in the national French CH registry and the French national health data system (SNDS). Of the 703 children recorded, 484 (68.8%) were linked. We retrospectively examined reimbursement for oral levothyroxine (LT4) between January 1, 2006, and December 31, 2017. Children who had discontinued treatment for 6 months or more before December 31, 2017, were classified as having TCH. We used a Cox model to examine the factors associated with TCH. Among the main study sample (n = 471), 53.5% were female, 14.2% were preterm, and 13.8% had low birth weight. One-quarter (n = 111, 24.3%) had mild CH (thyroid-stimulating hormone [TSH] < 50 mU/L, serum) at diagnosis and a median LT4 dose at treatment initiation of 30 μg/day. One-third (n = 155, 32.9%) had TCH. Premature birth (adjusted hazard ratio = 2.1 [1.0-4.2]), a TSH < 50 mU/L at CH screening (7.4 [3.2-17.1]), LT4 dose received at 12 months of age (0.98 [0.97-0.99, P = 0.003]), congenital cardiac malformations (6.6 [1.5-29.0]), and year of birth (1.2 [1.1-1.4]) were all associated with TCH. One-third of the children had TCH, and it was associated with several characteristics at birth and postpartum. These data are useful for CH medical management and epidemiological surveillance.

Identifiants

pubmed: 34850038
pii: 6444906
doi: 10.1210/clinem/dgab854
doi:

Substances chimiques

Thyrotropin 9002-71-5
Thyroxine Q51BO43MG4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1501-e1509

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Yaya Barry (Y)

Santé Publique France, the French National Public Health Agency, Non-Communicable Diseases and Trauma Division, Saint-Maurice, France.

Laurence Mandereau-Bruno (L)

Santé Publique France, the French National Public Health Agency, Data Science Division, Saint-Maurice, France.

Christophe Bonaldi (C)

Santé Publique France, the French National Public Health Agency, Data Science Division, Saint-Maurice, France.

David Cheillan (D)

Univ Lyon, CarMeN laboratory, INSERM- U1060, INRAE, INSA Lyon, Université Claude Bernard Lyon 1, Charles Mérieux Medical School, Pierre-Bénite, France.
Hospices Civils de Lyon, Lyon, France.
Unité Maladies Héréditaires du Métabolisme, Service de Biochimie et Biologie Moléculaire Grand Est, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France.

Régis Coutant (R)

CHU-Angers, Unité Endocrinologie Diabétologie Pédiatrique and Centre des Maladies Rares de la Réceptivité Hormonale, Angers, France.

Juliane Léger (J)

Department of Pediatric Endocrinology Diabetology, Reference Centre for Endocrine Growth and Development Diseases, Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), UMR, DHU Protect, Paris, France.
Paris Diderot University, Sorbonne Paris Cite´, Paris, France.

Nolwenn Regnault (N)

Santé Publique France, the French National Public Health Agency, Non-Communicable Diseases and Trauma Division, Saint-Maurice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH